GMAB
DependentGenmab
$1,804.00
+0.78%
as of 17 Apr
Power Core
Genmab's moat is genuine but narrow: its proprietary antibody engineering platforms, primarily DuoBody (bispecific antibodies) and HexaBody (hexameric antibody formats), produce molecules that larger pharmaceutical companies license because internal discovery cannot replicate the platform economics.
Direction of Movement
lateral
ROC 200
+39.4%
Direction Signals
- DARZALEX royalty revenue remains the dominant income driver but has entered the late growth phase. Subcutaneous formulation extends commercial life, but the patent cliff is visible on the horizon. Biosimilar entry is scheduled in phases through 2029 to 2032 across major markets.
- Epcoritamab (Epkinly) is scaling as a launch product with AbbVie. Revenue contribution is growing but has not yet reached the scale required to offset DARZALEX decline.
- Analyst consensus revenue trajectory projects 4.27 billion USD in 2026, 5.04 billion USD in 2027, 6.07 billion USD in 2028, rising to 6.43 billion USD by 2030. The compound rate of approximately 11% through 2030 is a decelerating trajectory relative to historical growth, consistent with a company transitioning from royalty growth to commercial build-out.
- ProfoundBio acquisition completed in 2024 at approximately 1.8 billion USD represented the largest M&A transaction in Genmab's history. The rationale was explicit: acquire antibody-drug conjugate capability to build owned commercial assets.
Genmab occupies one of the most unusual structural positions in European biotechnology. It is a highly profitable antibody developer based in Copenhagen with a market capitalization of approximately 111 billion DKK, a 25.9% net profit margin in 2025, and a research intensity (R&D at 41.9% of revenue) that would bankrupt a conventional pharmaceutical company. Yet its profitability is not primarily the product of its own commercial infrastructure. The dominant driver of Genmab's economics is a royalty stream on DARZALEX (daratumumab), a multiple myeloma therapy discovered by Genmab and commercialized worldwide by Johnson & Johnson's Janssen unit. J&J sells the drug. Genmab collects a tiered royalty. That structure has produced a decade of compounding cash flow, a 22 billion DKK cash cushion at peak, and the financial freedom to build an internal pipeline.
The central analytical observation for Genmab is this: the company is a Dependent whose platform technology is genuinely differentiated, whose balance sheet is genuinely strong, and whose long-term survival as an independent entity is genuinely contingent on executing a transition it has not yet proven it can complete. DARZALEX patent protection erodes through the late 2020s. The subcutaneous formulation extends exclusivity but does not eliminate the cliff. Every year that passes without an owned commercial asset of comparable scale is a year closer to a revenue reset that analyst models already quantify.
This is not a story about a failing company. Genmab delivered 3.86 billion USD in revenue in 2025 and generated 1.23 billion USD in operating cash flow. The question is structural: does a company whose largest asset is a royalty on someone else's marketed product qualify as a Status-Quo-Player in antibody therapeutics, or is it a high-quality Dependent whose moat must be continuously reconstructed? The data answers that question. The royalty receivable is the oxygen. Everything else is the patient breathing on borrowed time, using that oxygen to build new lungs.
This analysis continues with 6 more sections.
Continue reading: Role Assignment · Strategic Environment · Dependency Matrix · Self-Image & Mission · Direction of Movement · Portfolio Lens
Read full analysis — freeCreate a free account. No credit card. No trial period.